华控赛格（000068）11月28日晚间发布公告称，公司于2025年11月27日召开第八届董事会第十七次临时会议，审议通过了《关于主动终止向特定对 象发行股票的议案》，同意公司终止向特定对象发行股票事项。 华控赛格筹划此次定增由来已久。早在2023年8月7日，公司就召开第七届董事会第二十一次临时会议、第七届监事会第十五次临时会议，于2023年 11月27日召开2023年第二次临时股东会，审议通过了《关于公司 <向特定对象发行a股股票预案> 的议案》《关于提请股东大会授权董事会全权办理 公司2023年度向特定对象发行股票相关事宜的议案》。 不过，2024年12月2日公司召开2024年第二次临时股东会，审议通过了《关于延长向特定对象发行股票股东大会决议和授权有效期的议案》，向特定 对象发行股票项目有效期自前次有效期届满之日起延长12个月（延长至2025年12月11日）。 华控赛格原拟向控股股东华融泰发行股票募集资金总额不超过8.46亿元，扣除发行费用后净额全部用于偿还有息借款。 彼时，华控赛格资产负债率高达90.19%，长期借款达9.39亿元，负债率较高，有息债务较重，项目占用资金较大，应收账款与合同资产占比较高 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. has made significant decisions during its board meeting, including the termination of a simplified procedure for issuing A-shares and the acquisition of a 15% stake in its subsidiary, which reflects the company's strategic focus on enhancing control and management efficiency [1][2][3] Group 1: Board Meeting Details - The seventh board meeting was held on August 29, 2025, with all nine directors present, and the meeting's procedures complied with relevant laws and regulations [1] - The board unanimously agreed to terminate the simplified procedure for issuing A-shares, indicating a careful decision-making process that will not adversely affect the company's operations or shareholder interests [1][2] Group 2: Acquisition of Subsidiary Stake - The company plans to exercise its right of first refusal to acquire 15% of the shares from minority shareholders of its subsidiary, Chengdu Xinno Ming Biotechnology Co., Ltd., with a purchase price not exceeding RMB 45 million [2][3] - This acquisition is aligned with the company's strategic development goals and aims to enhance control over the subsidiary, thereby improving overall management efficiency [2][3]

Core Viewpoint - Huaye Spice has decided to terminate the plan for a simplified procedure to issue shares to specific targets for the year 2025, which was initially intended to raise a total of 113 million yuan for the first phase of a spice production project [1][2] Group 1: Termination of Share Issuance - The decision to terminate the share issuance was made after careful consideration of the company's current situation and future development plans, following discussions with relevant parties [2] - The company will continue to advance the construction of the 1,300-ton spice production facility using its own and self-raised funds [2] - The termination of the share issuance will not have a significant adverse impact on the company's operations and business development [2] Group 2: Shareholder Reduction Plans - The controlling shareholder and actual controller, Hua Wenliang, plans to reduce his holdings by up to 2,243,940 shares, accounting for 3% of the total share capital [3] - The reduction will occur within three months after the announcement, with a maximum of 1% through centralized bidding and 2% through block trading [3] Group 3: Financial Performance - In the first half of 2025, Huaye Spice achieved operating revenue of 192 million yuan, a year-on-year increase of 11.05% [5] - The net profit attributable to shareholders was 20.9965 million yuan, representing a year-on-year growth of 52.76% [5] - The net profit after deducting non-recurring gains and losses was 21.0989 million yuan, showing a significant increase of 76.63% year-on-year [6]